Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depression - Major Depressive Disorder
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this project is to quantify the relative effectiveness of aerobic exercise monitored by smart wristbands in assisting the treatment of depression and improving cognitive function. It aims to explore the mechanisms through which aerobic exercise exerts its effects using imaging genetics and other methods, and to identify suitable populations for exercise, ultimately providing personalized clinical exercise prescriptions. This study will intervene from a behavioral perspective and also seeks to motivate participants to change and improve their physical activity habits.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Aerobic exercise — Moderate-intensity aerobic exercise for 30-50 minutes three times a week was added to usual medical therapy

Primary Outcomes

  • Change from baseline in Hamilton Depression Rating Scale (HAMD) (Week 4 and 8 of treatment duration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-12
Completion: 2025-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University
Contact Information
Study Contact:
Weihua Yue, Doctor
86-010-82805307
dryue@bjmu.edu.cn
Guorui Zhao
86-13661352950
grzhao@bjmu.edu.cn
Weihua Yue, Doctor
010-82805307
dryue@bjmu.edu.cn
Peking University Sixth Hostipal
Interventions
  • Behavioral: Aerobic exercise — Moderate-intensity aerobic exercise for 30-50 minutes three times a week was added to usual medical therapy
Study Locations (1 sites)
Peking University Sixth Hostipal, Beijing, Beijing Municipality 100191 China
Eligibility Criteria
Inclusion Criteria: 1. Aged 18-45 years (including 18 and 45), no gender restriction; 2. Meets the diagnostic criteria for depressive disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V); 3. Outpatients or inpatients; Hamilton Depression Rating Scale 17-item (HAMD-17) score ≥ 14; Mood Disorder Questionnaire (MDQ) screening negative to exclude bipolar disorder patients; and Clinical Global Impressions-Severity (CGI-S) score ≥ 4; 4. Maintained on antidepressant treatment for at least 4 weeks or not using antidepressant treatment; 5. Written informed consent obtained from the patient. Exclusion Criteria: 1. Diagnosed with other mental disorders, including schizophrenia, bipolar disorder, alcohol or substance abuse/dependence, eating disorders, etc.; 2. Individuals with intellectual disabilities or who are unable to cooperate for other reasons, or those lacking or having incomplete civil capacity during the onset of illness; 3. Suffering from neurological or organic brain diseases (such as stroke, cerebral hemorrhage, brain tumors, Parkinson's disease, epilepsy, etc.) and a history of severe traumatic brain injury; 4. Suffering from conditions with high exercise risk, such as hypertension or heart disease; 5. Currently undergoing systematic psychological therapy; 6. In the 3-minute step test, males with a recovery heart rate more than131 and females with a recovery heart rate more than 140; 7. Physically restricted individuals unable to participate in physical exercise; 8. Physical Activity Readiness Questionnaire (PAR-Q) score ≥ 2; 9. Pregnant women or individuals with contraindications to MRI examinations; 10. Individuals with severe suicidal tendencies or at risk of harming others.
Conditions Triple Negative Breast Cancer (TNBC)
Phase PHASE2
Enrollment 129
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

All trans retinoic acid Combined with Toripalimab+Chemotherapy for Locally Advanced inoperable or Metastatic Triple Negative Breast Cancer:a multi-center, multi-cohort phase II trial

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Cohort2: ATRA+Toripalimab+TPC — Receive 200 mg D1 of Toripalimab via intravenous infusion for a course of 21 days; TPC regimen (monoclonal antibody 10mg/kg D1, 8 intravenous infusions, 1 course of treatment every 21 days; Elibulin 1.4mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Utideron 40mg/m2 D1-5 intravenous infusions, 1 course of treatment every 21 days; Gemcitabine 1000mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Albumin paclitaxel 100 mg/m2 D1, D8, intravenous infusion, 1 course of treatment every 21 days); Capecitabine 1000mg/m2, D1-14, oral, one course of treatment every 21 days); All trans retinoic acid 20 mg bid, orally, D-3-D11, administered continuously for 14 days, stopped for 7 days, with one course of treatment lasting 21 days.
  • Drug: Cohort1: ATRA+Toripalimab+chemo — Receive 200 mg of Toripalimab via D1 intravenous infusion, with 21 days as one course of treatment; Albumin paclitaxel 100 mg/m2, D1, D8, intravenous infusion, one course of treatment for 21 days; All trans retinoic acid 20 mg bid, oral, D-3-D11, continuous administration for 14 days, cessation for 7 days, 21 days is one course of treatment.

Primary Outcomes

  • Objective Response Rate (ORR) (up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-11-04
Completion: 2029-09
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 129 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Zhonghua Tao, MD
86 13774315805
drtaozhh@126.com
Hongxia wang, PHD
02164175590
whx365@126.com
Fudan University Shanghai Cancer Center
hongxia wang, PHD
Fudan University Shanghai Cancer Center
Interventions
  • Drug: Cohort2: ATRA+Toripalimab+TPC — Receive 200 mg D1 of Toripalimab via intravenous infusion for a course of 21 days; TPC regimen (monoclonal antibody 10mg/kg D1, 8 intravenous infusions, 1 course of treatment every 21 days; Elibulin 1.4mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Utideron 40mg/m2 D1-5 intravenous infusions, 1 course of treatment every 21 days; Gemcitabine 1000mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Albumin paclitaxel 100 mg/m2 D1, D8, intravenous infusion, 1 course of treatment every 21 days); Capecitabine 1000mg/m2, D1-14, oral, one course of treatment every 21 days); All trans retinoic acid 20 mg bid, orally, D-3-D11, administered continuously for 14 days, stopped for 7 days, with one course of treatment lasting 21 days.
  • Drug: Cohort1: ATRA+Toripalimab+chemo — Receive 200 mg of Toripalimab via D1 intravenous infusion, with 21 days as one course of treatment; Albumin paclitaxel 100 mg/m2, D1, D8, intravenous infusion, one course of treatment for 21 days; All trans retinoic acid 20 mg bid, oral, D-3-D11, continuous administration for 14 days, cessation for 7 days, 21 days is one course of treatment.
Study Locations (2 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Fudan University Shanghai Cancer Center, Shanghai, China
Eligibility Criteria
Inclusion Criteria: 1. The subjects voluntarily participate and sign a written informed consent form; 2. Age ≥ 18 years old; 3. For locally advanced inoperable or metastatic breast cancer confirmed by histology (according to AJCC 8th edition staging), the histology and pathology clearly showed that ER, PR, Her-2 were negative. If there was metastatic lesion pathology, the metastatic lesion histology and pathology should prevail. The definition of ER and PR negativity is: IHC ER\<1%, IHC PR\<1%. Her-2 negativity is defined as: immunohistochemical detection of Her-2 (-) or (1+), Her-2 (2+) must undergo FISH testing and the result is negative, Her-2 (-) or (1+) can choose to undergo FISH testing and the result is negative; 4. According to RECIST 1.1 criteria for solid tumor evaluation, there must be at least one measurable lesion; 5. Cohort 1: For locally advanced non operable or metastatic TNBC that has not been previously treated, intravenous chemotherapy and anti-tumor therapy may be used during previous neoadjuvant and/or adjuvant therapy stages, provided that the interval between the end of neoadjuvant and/or adjuvant therapy and the occurrence of recurrence/metastasis is ≥ 12 months; Cohort 2: Local late stage inoperable or metastatic TNBC with previous treatment failures of at least one line or above; 6. All subjects should undergo tumor lesion biopsy during the screening period to obtain sufficient qualified tumor tissue specimens for retrospective biomarker analysis (including PD-L1 expression levels) in their cohort. If subjects are unable to undergo biopsy, they should provide tumor samples or unstained sections (3-5 μm) that have been fixed in formalin and embedded in paraffin (FFPE) closest to the start of the study treatment (up to 24 months) for corresponding biomarker analysis; 7. The main organ function is good, the relevant examination indicators within 14 days before treatment meet the following requirements: Without blood transfusion, platelet count ≥ 100 × 10\^9/L, hemoglobin ≥ 90g/L, neutrophil count (ANC) ≥ 1.5 × 10\^9/L AST and ALT ≤ 2.5 x upper limit of normal (ULN), ≤ 5 x ULN if liver metastasis is present, total bilirubin ≤ 1.5 x ULN, serum creatinine (Cr) ≤ 1.5 ULN, or creatinine clearance rate ≥ 60mL/min (Cockcroft Gault formula) 8. Expected survival period ≥ 3 months; 9. ECOG PS score: 0-1 points; 10. Non surgical sterilization, male patients with women of childbearing age or partners of childbearing age, are required to use a medically approved contraceptive measure (such as intrauterine device, contraceptive pill, or condom) during the study treatment period and within 6 months after the end of the study treatment period; Female patients of childbearing age who undergo non-surgical sterilization must have a negative serum HCG test within 72 hours prior to enrollment in the study. Exclusion Criteria: 1. Individuals who have previously been treated with PD-1 or PD-L1 monoclonal antibodies; Participants in cohort 1 who have previously used albumin paclitaxel; 2. Individuals known to be allergic to any of the drugs in the study; 3. Patients who have hypersensitivity reactions to other vitamin A drugs; 4. History of active autoimmune diseases requiring systemic treatment in the past 2 years (e.g. corticosteroids (dose ≤ 10mg/day, except for prednisone or other effective hormones) or immunosuppressive drugs); 5. Diagnosed with immune deficiency or undergoing systemic steroid therapy (excluding doses ≤ 10mg/day of prednisone or other effective hormones) or any other form of immunosuppressive therapy within 7 days prior to enrollment; 6. There are other known malignant tumors that have progressed or require active treatment in the past 5 years. Excluding malignant tumors that can be treated locally and have already been cured, such as skin basal cell carcinoma, skin squamous cell carcinoma, and cervical cancer in situ; 7. Known to have active central nervous system (CNS) metastases; 8. History of non infectious pneumonia requiring steroid hormone therapy; 9. Active infections require systematic treatment; 10. There are serious uncontrolled hypertension, diabetes and hyperlipidemia; 11. History of II-IV congestive heart failure or myocardial infarction within 6 months prior to enrollment; 12. Individuals who tested positive for HIV during screening; 13. Active hepatitis (hepatitis B reference: HBsAg positive and HBV DNA ≥ 500 IU/ml; hepatitis C reference: HCV antibody positive and HCV copy number\>upper limit of normal value); 14. Individuals with other serious acute or chronic physiological or mental problems; 15. Accepting any medication that is prohibited from being used in combination with the investigational drug, unless the medication has been discontinued within 7 days prior to enrollment; 16. Lactating women; 17. Individuals who have participated in clinical trials of other anti-tumor drugs within the past four weeks; 18. Inability to swallow, intestinal obstruction, or other factors that affect medication administration and absorption; 19. Any situation that other researchers consider unsuitable for participation in this study.
Conditions Prediabetic State, Life Style, Intervent...
Phase NA
Enrollment 324
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Nearly half of adults in the United States have or are at risk of developing type 2 diabetes. The overall goal of this community-engaged research is to examine the efficacy of an innovative couple-based lifestyle intervention to prevent type 2 diabetes that is applicable to a broad range of partnered adults in the United States. By simultaneously targeting lifestyle and perceived support from romantic partners, there is a high likelihood of creating lasting changes in both

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Individual intervention condition (PreventT2) — PreventT2 will be delivered by a team of trained CDC National Diabetes Prevention Program (NDPP) Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the lifestyle intervention curriculum to be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National DPP, which has Full recognition from the CDC based on outcome data over the course of a number of years.
  • Behavioral: Couple-based intervention condition (PreventT2 Together; couple-based adaptation of 2021 PreventT2; approved by the CDC in November 2022 as an Alternate Curriculum for use in the NDPP) — PreventT2 Together will be delivered by a team of trained CDC National DPP Lifestyle Coaches to adults at high risk for diabetes and their partners. The lifestyle intervention curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (Diabetes Prevention Program) (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevent type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.

Primary Outcomes

  • Percent of target partners achieving clinically meaningful increases in Moderate to Vigorous Physical Activity (MVPA) (14 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-06
Completion: 2028-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 324 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Utah
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Katherine JW Baucom, PhD (PRINCIPAL_INVESTIGATOR) - University of Utah
Contact Information
Study Contact:
Elizabeth Z Beaulieu, B.S.
801-696-3757
elizabeth.beaulieu@psych.utah.edu
Katherine JW Baucom, PhD
katherine.baucom@psych.utah.ed
Elizabeth Z Beaulieu, BS
801-696-3757
heartlab@psych.utah.edu
University of Utah
Interventions
  • Behavioral: Individual intervention condition (PreventT2) — PreventT2 will be delivered by a team of trained CDC National Diabetes Prevention Program (NDPP) Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the lifestyle intervention curriculum to be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National DPP, which has Full recognition from the CDC based on outcome data over the course of a number of years.
  • Behavioral: Couple-based intervention condition (PreventT2 Together; couple-based adaptation of 2021 PreventT2; approved by the CDC in November 2022 as an Alternate Curriculum for use in the NDPP) — PreventT2 Together will be delivered by a team of trained CDC National DPP Lifestyle Coaches to adults at high risk for diabetes and their partners. The lifestyle intervention curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (Diabetes Prevention Program) (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevent type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
Study Locations (1 sites)
University of Utah, Salt Lake City, Utah 84112 United States
Eligibility Criteria
Inclusion Criteria: 1. "Target partner" is eligible for the National DPP per CDC eligibility requirements: * BMI ≥ 25 kg/m² (≥ 23 kg/m² if Asian American), and * Do not have a diagnosis of type 1 or type 2 diabetes, and * Not currently pregnant, and * High risk for type 2 diabetes based on: (i) CDC Prediabetes Risk Test score ≥ 5, (ii) clinically diagnosed Gestational Diabetes during a previous pregnancy (for women), or (iii) a blood test result indicative of prediabetes in the past year (i.e., fasting blood glucose 100-125 mg/dl; plasma glucose 140-199 mg/dl measured 2 hours after a 75 g glucose load; or HbA1c 5.7%-6.4%). 2. The couple has lived together for 1+ years. 3. Both partners are willing to participate in the research. 4. Both partners are at least 18 years old. 5. Both partners are fluent in English. EXCLUSION CRITERIA: 1. "Supporting partner" has a diagnosis of Type 2 Diabetes. 2. Either partner: * Has a diagnosis of another chronic disease (unless no major events/changes for 3+ months), or * Is currently on medication or engaged in lifestyle intervention for prediabetes or obesity, or * Has previously participated in the National DPP, or * Reports discomfort participating in a lifestyle program with their partner, or * Reports a low level of relationship commitment (i.e., "4" or lower on a scale from 1 (do not agree at all) to 7 (agree completely) on the item "I want this relationship to stay strong no matter what rough times we encounter."; Owen et al., 2011).
Conditions Breastfeeding, Exclusive, Fatigue, Sleep...
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The postnatal period is a risky period in which mothers experience regressive and progressive changes and rapid biopsychosocial changes. Since this process affects not only the mother but also the family, mothers are under intense stress due to adaptation to the changes that occur in this period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Quadruple

Interventions / Regimen

  • Behavioral: MBSR — 20 minutes once a week for 8 weeks
  • Behavioral: NLP — NLP Neurolinguistic programming, 20 minutes once a week for 8 weeks
  • Behavioral: control — control group, no practice,

Primary Outcomes

  • Visual Analogue Scale for Fatigue (VAS-F) (before the first application)
  • Visual Analogue Scale for Fatigue (VAS-F) (Week 4)
  • Visual Analogue Scale for Fatigue (VAS-F) (Week 8)
  • Pittsburgh Sleep Quality Index (PSQI) (before the first application)
  • Pittsburgh Sleep Quality Index (PSQI) (week 4)
  • Pittsburgh Sleep Quality Index (PSQI) (week 8)
  • Bristol Breastfeeding Assessment Tool (BBAT) (before the first application)
  • Bristol Breastfeeding Assessment Tool (BBAT) (week 4)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-08
Completion: 2025-10-30
Eligibility
Age: 19 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aysegul Kilicli
Principal Investigators:
  • AYŞEGÜL KILIÇLI, Dr. (STUDY_DIRECTOR) - Muş Alparslan University
Contact Information
Study Contact:
AYŞEGÜL KILIÇLI, Dr.
04143181717
aysegul_ay_9@hotmail.com
AYŞEGÜL KILIÇLI, PhD.
04143180000
aysegul_ay_9@hotmail.com
AYŞEGÜL KILIÇLI
04143186000
aysegul_ay_9@hotmail.com
Şanlıurfa training and research hospital
Interventions
  • Behavioral: MBSR — 20 minutes once a week for 8 weeks
  • Behavioral: NLP — NLP Neurolinguistic programming, 20 minutes once a week for 8 weeks
  • Behavioral: control — control group, no practice,
Study Locations (1 sites)
Şanlıurfa training and research hospital, Sanliurfa, Eyalet/Yerleşke 63000 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * 19-35 years old * caesarean section * primiparous * breastfeeding women Exclusion Criteria: * women who refused to participate in the research.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 840
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to explore the relationship between psychological stress and the therapeutic response in breast cancer patients who have received standard neoadjuvant chemotherapy.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Exposure: psychological stress status — The assessment of depressive, anxiety or perceived Stress was conducted using PHQ-9, GAD-7 or PSS scale. Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 or a PSS score ≥ 20 were categorized as the stressed group.

Primary Outcomes

  • Pathologic complete response (pCR) rate (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-15
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 840 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shengjing Hospital
Contact Information
Study Contact:
Liu Hua, Ph. D
15140067366
20242027@cmu.edu.cn
Liu Cai Gang, Ph. D
15140067366
20242027@cmu.edu.cn
Niu Nan, MD
024-96615-31813
2951878628@qq.com
Shengjing Hospital of China Medical University
Interventions
  • Other: Exposure: psychological stress status — The assessment of depressive, anxiety or perceived Stress was conducted using PHQ-9, GAD-7 or PSS scale. Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 or a PSS score ≥ 20 were categorized as the stressed group.
Study Locations (1 sites)
Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004 China
Eligibility Criteria
Inclusion Criteria: * 1.Age ≥ 18 years; 2.Histological and/or cytological diagnosis of breast cancer; 3.Treatment niave patients; 4.To receive standard neoadjuvant therapy; 5.Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 6.Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ; 7.Informed and agreed to participate in the study; Exclusion Criteria: * 1\. Breast cancer has not been confirmed through histological or cytological examinations. 2.Other breast cancer conditions that do not receive neoadjuvant therapy. 3.Combined with other malignant tumors. 4.Concurrent acute or chronic psychiatric disorders, along with having received antidepressant or anti-anxiety therapy within the past month. 5.Participants must not have engaged in any other clinical trials in the past month, unless those trials are observational or non-interventional in nature.
Conditions Liver Cirrhosis, Ascites Hepatic, Portal...
Phase NA
Enrollment 134
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this clinical trial is to compare the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) implantation with standard treatment (diuretic medications, and if necessary, paracenteses) in patients with liver cirrhosis and development of ascites as the first decompensating event. By creating a shunt between the liver vein and the portal vein, blood is diverted from the portal vein directly into the hepatic vein, which results in a reduction of pressure in the portal vein so that development of ascites is reduced.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Transjugular intrahepatic portosystemic shunt (TIPS) — TIPS implantation is performed by creating a shunt between the liver vein and the portal vein to enable portal pressure reduction.

Primary Outcomes

  • Transplantation-free survival (TFS) (Through study completion, an average of 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-01
Completion: 2029-02-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 134 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital Freiburg
Collaborators: Jena University Hospital, Johannes Gutenberg University Mainz, University Hospital Muenster, University Hospital, Bonn, University Hospital Munich, Hannover Medical School, University of Leipzig, University Hospital, Aachen, University Hospital Lübeck, Heinrich-Heine University, Duesseldorf
Contact Information
Study Contact:
Dominik Bettinger, MD
+4976127036870
dominik.bettinger@uniklinik-freiburg.de
Marco Janoschke, PhD
+4976127077831
marco.janoschke@uniklinik-freiburg.de
Dominik Bettinger, Prof. Dr.
+4976127036870
dominik.bettinger@uniklinik-freiburg.de
University Medical Center Freiburg
Interventions
  • Procedure: Transjugular intrahepatic portosystemic shunt (TIPS) — TIPS implantation is performed by creating a shunt between the liver vein and the portal vein to enable portal pressure reduction.
Study Locations (1 sites)
University Medical Center Freiburg, Freiburg im Breisgau, 79106 Germany
Eligibility Criteria
Inclusion Criteria: Patients eligible for inclusion in this trial must meet all of the following criteria: 1. Patients ≥ 18 years and \< 80 years 2. Liver cirrhosis as documented by previous liver biopsy or by a combination of typical clinical, biochemical and sonographic features 3. Ascites as the first single decompensating event with grade 2 ascites and MELD ≥ 15 OR grade 3 ascites 4. INR ≤ 1.5 5. Ability to understand the nature of the trial and the trial related procedures and to comply with them Exclusion Criteria: Patients eligible for this trial must not meet any of the following criteria: 1. Treatment refractory or recurrent ascites at the time of study inclusion 2. Patients with concomitant variceal bleeding fulfilling the criteria for pre-emptive TIPS implantation (Child-Pugh class C \< 14 points or Child-Pugh class B \>7 with active bleeding at initial endoscopy or hepatic venous pressure gradient \[HVPG\] \> 20 mmHg at the time of bleeding) 3. Budd-Chiari syndrome 4. Portal vein thrombosis (PVT) 5. Spontaneous bacterial peritonitis (SBP) 6. Uncontrolled systemic infection (defined as an increase of \> 20% if inflammatory parameters \[C-reactive protein, procalcitonin, leukocytes\] and/or sepsis as a reason for development of ascites 7. Cardiac cirrhosis (defined as the development of liver cirrhosis in a patient with cardiac heart failure due to primary cardiac disease) 8. Clinical significant cardiac disease (NYHA ≥II) 9. Untreated valvular heart disease: middle to high-grade valve stenosis or insufficiency (applies to mitral, tricuspid, aortic and pulmonary valves) 10. Diastolic dysfunction grade III, stated by transthoracic echocardiogram (TTE) 11. Reduced left ventricular ejection fraction ≤50% 12. Pulmonary hypertension (mean pulmonary arterial pressure \> 45 mmHg) 13. Bilirubin \> 3 mg/dl 14. Obstructive cholestasis 15. Hepatorenal syndrome type AKI (HRS-AKI) 16. Acute on chronic liver failure 17. Benign liver tumor within the potential puncture tract 18. Patient after liver transplantation 19. Prior TIPS implantation 20. Ongoing and/or recurrent hepatic encephalopathy (grade \>II) 21. Active tumor disease including hepatocellular carcinoma defined as need for chemotherapy, radiation therapy, interventional or surgical treatment 22. New onset of antiviral treatment for chronic hepatitis B virus (HBV) infection within the last 3 months 23. Untreated chronic hepatitis C virus (HCV) infection 24. Life expectancy \<1 year 25. Pregnant or breastfeeding women 26. Patients without the legal capacity who are unable to understand the nature, significance and consequences of the study 27. Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed 28. Person who is in a relationship of dependence/employment with the sponsor or the investigator
Conditions Post Coronary Artery Bypass Grafting, Hy...
Phase NA
Enrollment 536
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the effect of an AI-assisted "Smart family doctor" digital health management tool on improving the control rates of hypertension, diabetes, and dyslipidemia in post-CABG (coronary artery bypass grafting) patients or post-PCI (percutaneous coronary intervention) patients. A randomized controlled trial design will be used, involving approximately 5-10 hospitals and 536 participants. Eligible participants are adults aged 18 or older, post-CABG or post-PCI patients with hypertension, diabetes, and dyslipidemia.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Smart family doctor — Based on health managers, participants were additionally provided "Smart family doctor", which is an AI-assisted applications with personalized interactions. The content includes, but is not limited to: (1) General educational content, covering basic health knowledge on diseases, risk factors, and treatment methods; (2) Targeted health information, such as more specific guidance on blood pressure and blood sugar control, medication adherence, exercise, and smoking cessation; (3) Personalized disease management guidance, providing tailored reminders for patients regarding medication, diet, exercise, and medical visits. Patients can also directly report their latest self-measured blood pressure, blood lipid, blood sugar levels, and medication adherence to receive treatment and medication guidance from the 'Smart family doctor'.
  • Behavioral: Health manager — Participants will received 3-hour health management guidance from a health manager once a week, including guidance on healthy lifestyle, medication treatment, and rehabilitation advice. The research team will provide participants with one smart band, requiring them to wear the band daily to collect health data during the 6-month study period.

Primary Outcomes

  • The control rates of hypertension, diabetes and hyperlipidemia (6-month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-24
Completion: 2026-11-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 536 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China National Center for Cardiovascular Diseases
Collaborators: Chinese Academy of Medical Sciences, Fuwai Hospital
Principal Investigators:
  • Xin Yuan, PhD (PRINCIPAL_INVESTIGATOR) - Chinese Academy of Medical Sciences, Fuwai Hospital
Contact Information
Study Contact:
Lihua Zhang Zhang, PhD
8601060866780
zhanglihua@fuwai.com
Zhiying Wen
+8618129344576
leilubi@fuwai.com
Xinjiang's First Affiliated Hospital of medical university
Interventions
  • Behavioral: Smart family doctor — Based on health managers, participants were additionally provided "Smart family doctor", which is an AI-assisted applications with personalized interactions. The content includes, but is not limited to: (1) General educational content, covering basic health knowledge on diseases, risk factors, and treatment methods; (2) Targeted health information, such as more specific guidance on blood pressure and blood sugar control, medication adherence, exercise, and smoking cessation; (3) Personalized disease management guidance, providing tailored reminders for patients regarding medication, diet, exercise, and medical visits. Patients can also directly report their latest self-measured blood pressure, blood lipid, blood sugar levels, and medication adherence to receive treatment and medication guidance from the 'Smart family doctor'.
  • Behavioral: Health manager — Participants will received 3-hour health management guidance from a health manager once a week, including guidance on healthy lifestyle, medication treatment, and rehabilitation advice. The research team will provide participants with one smart band, requiring them to wear the band daily to collect health data during the 6-month study period.
Study Locations (1 sites)
Xinjiang's First Affiliated Hospital of medical university, Ürümqi, Xinjiang 102300 China
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years. * History of CABG surgery or PCI with history of hypertension, diabetes, and dyslipidemia. * At least one of the following criteria is meet: * Systolic blood pressure no less than 130 mmHg or diastolic blood pressure no less than 80 mmHg * HbA1c no less than 7% * LDL-C no less than 1.4 mmol/L * Use of a smartphone. * Signed informed consent. Exclusion Criteria: * History of heart failure or severe arrhythmias. * Presence of other severe underlying conditions such as cancer or liver and kidney insufficiency. * Pregnancy, lactation, or plans for pregnancy within the next year. * Cognitive, communication impairments, or limitations in daily activities.
Conditions Bipolar Depression
Phase NA
Enrollment 10
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is only enrolling at Baylor College of Medicine. The other research locations listed serve to support data analysis only. This research study is to investigate the use of technology called Deep Brain Stimulation (DBS) to potentially improve Treatment-Resistant Bipolar Depression (TRBD) symptoms in patients with severe cases. DBS involves the surgical implantation of leads and electrodes into specific areas of the brain, which are thought to influence the disease. A pack implanted in the chest, called the neurotransmitter, keeps the electrical current coursing to the brain through a wire that connects the neurotransmitter and electrodes. It is believed DBS may restore balance to dysfunctional brain circuitry implicated in TRBD. The goal of this study is to enhance current approaches to DBS targeting in the brain and to use a novel approach to find a better and more reliable system for TRBD treatment. Its important for participants to understand that this is an investigational study where there could be a lack of effectiveness in improving TRBD symptoms. There may be no directly benefit from taking part in this study. This study is expected to last 20 months and involves 3 main steps. 1. Medical, psychiatric, and cognitive evaluations. 2. Implantation of a brain stimulation system. 3. Follow up after implantation of device, including programming, recording, and psychiatric testing. There are risks and benefits to this study which need to be considered when deciding to participate or not. Some of the risks are from surgery, the DBS device and programming, the tests involved, and potential loss of confidentiality, as well as other unknown risks. Some of the more serious risks involved in this study and the percentage that they occur: 1. Bleeding inside the Brain (1 to 2 percent). 2. Infection from the procedures (3 percent) 3. Seizure caused from the procedures (1.2 percent) However, the benefit of this study is that it may help relieve or decrease TRBD symptoms. This form of treatment has shown to reduce symptom severity in other cases. This could potentially improve quality of life and activities in daily routines. There is also a potential benefit to society in that the data the investigators will obtain from this study may help increase the understanding of the mechanisms underlying TRBD symptoms, as well as enhanced Deep Brain Stimulation techniques. Study participation is expected to last 20 months from the time the DBS device is activated and should include approximately 23 visits. These visits also include 8 separate, 24 hour stays at the Menninger NeuroBehvaioral Monitoring Unit (NBU). These 24-hour sessions will occur at multiple points throughout the study (1 week prior to surgery, the week preceding device activation, the week following activation, then after 2 weeks, 4 weeks, 6 months, 9 months, and 12 months). Participants will need to stay locally for the week of the NBU stay (typically Monday through…

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Medtronic Percept RC System — Medtronic Percept RC System includes: Percept RC neurostimulator SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Extension Kit (with and without marker; 40cm, 60cm, and 95cm lengths) Percept DBS Handset and Communicator Kit (patient programmer) SenSight Extension Tunneler Kit SenSight Burr Hole Device Kit Clinician Programmer Application (application runs on Model CT900 Tablet) Percept RC Recharger Kit Recharge Application Software Clinician Communicator/Telemetry Module
  • Behavioral: One Month Blinded Discontinuation Period — The investigators will use blinded discontinuation at 12 months rather than sham control to establish evidence that response is dependent on ongoing DBS. The open-label design allows for personalized optimization of programming settings - a strength of this design as related to our study goals. Although one of the goals of this study is to use neural recordings to inform programming, currently, unblinded programming is needed to maximize response and minimize side effects. Adverse events will be elicited at each study visit using a standardized instrument, the Patient-Rated Inventory of Side Effects (PRISE). In addition to monitoring for adverse events related to surgery and stimulation, the investigators will track quality of life (QOLS), global functioning (SDS), and necessary adjustments of medications. The behavioral changes of the subject based on these scales will provide insight to the intervention levels provided from discontinuing the therapy from the device.

Primary Outcomes

  • Utilizing the Montgomery-Asberg Depression Ratings Scale (MADRS) as a measurement of Efficacy (20 months)
  • Utilizing the Patient-Rated Inventory of Side Effects (PRISE) assessment for adverse events/side effects (20 months)
  • Evaluation of manic episodes utilizing the Young Mania Rating Scale (YMRS) (20 months)
  • Evaluation of manic episodes utilizing the Altman Self-Rating Mania Scale (ASRM) (20 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2030-05-30
Eligibility
Age: 22 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wayne Goodman MD
Collaborators: University of Washington, William Marsh Rice University, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS)
Principal Investigators:
  • Wayne Goodman, MD (PRINCIPAL_INVESTIGATOR) - Baylor College of Medicine
Contact Information
Study Contact:
Michelle Avendano
713-798-4729
mavendan@bcm.edu
Luke Jumper
713-798-4113
jumper@bcm.edu
Michelle Avendano
713-798-4729
mavendan@bcm.edu
Baylor College of Medicine
Interventions
  • Device: Medtronic Percept RC System — Medtronic Percept RC System includes: Percept RC neurostimulator SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Extension Kit (with and without marker; 40cm, 60cm, and 95cm lengths) Percept DBS Handset and Communicator Kit (patient programmer) SenSight Extension Tunneler Kit SenSight Burr Hole Device Kit Clinician Programmer Application (application runs on Model CT900 Tablet) Percept RC Recharger Kit Recharge Application Software Clinician Communicator/Telemetry Module
  • Behavioral: One Month Blinded Discontinuation Period — The investigators will use blinded discontinuation at 12 months rather than sham control to establish evidence that response is dependent on ongoing DBS. The open-label design allows for personalized optimization of programming settings - a strength of this design as related to our study goals. Although one of the goals of this study is to use neural recordings to inform programming, currently, unblinded programming is needed to maximize response and minimize side effects. Adverse events will be elicited at each study visit using a standardized instrument, the Patient-Rated Inventory of Side Effects (PRISE). In addition to monitoring for adverse events related to surgery and stimulation, the investigators will track quality of life (QOLS), global functioning (SDS), and necessary adjustments of medications. The behavioral changes of the subject based on these scales will provide insight to the intervention levels provided from discontinuing the therapy from the device.
Study Locations (4 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Baylor College of Medicine, Houston, Texas 77030 United States
Rice University, Houston, Texas 77030 United States
University of Washington, Seattle, Washington 98195 United States
Eligibility Criteria
Inclusion Criteria: 1. Males and females ages 22-64, inclusive 2. Diagnosis: Bipolar I disorder confirmed by SCID-5, currently in a major depressive episode (MDE). 3. Symptom Severity: MADRS score of ≥27 at Screening and pre-operative baseline visit. CGI-S \> 4 and YMRS \<12 at these visits. 4. Failure to respond or maintain a response to a minimum of four evidence-based interventions for bipolar depression in the patient's lifetime, including at least two FDA-approved medications (olanzapine/fluoxetine, quetiapine, lurasidone, cariprazine, lumateperone), or ECT, administered at adequate doses and duration (adequately defined by the Antidepressant Treatment History Form (ATHF-Short Form). During the current episode, the patient must have failed to respond or maintain a response to a minimum of two FDA-approved interventions for bipolar depression. In addition, the patient is required to be currently taking at least one evidence-based medication for bipolar disorder (e.g., lithium, either alone or in combination with an atypical antipsychotic such as quetiapine), unless no evidence-based medications for bipolar disorder are tolerated. 5. Initial mood episode occurred before the age of 40 - to minimize risk of enrolling patients with so atypical onset of initial mania/depression. 6. Must be on a stable dose of psychotropic medications for a minimum of four weeks prior to surgery. 7. Minimum score on the Montreal Cognitive Assessment (MoCA). 8. Able and willing to give informed consent and sign Treatment Contract that includes identification of a reliable informant. Exclusion Criteria: 1. Lifetime history of a psychotic disorder (e.g., schizophrenia, schizoaffective disorder, and other psychotic disorders), or any history of psychotic symptoms when not in a bipolar mood episode. 2. Currently meets criteria for a manic or hypomanic episode or rapid cycling (4 or more mood episodes in the previous 12 months). 3. Any psychiatric disorder which is the primary focus of treatment within the past 12 months (with bipolar disorder as the secondary focus of treatment). 4. Alcohol/substance use disorder, moderate or severe, within the previous 12 months \[excluding nicotine\]. 5. Intellectual disability or neurocognitive disorder. 6. Current major and/or unstable medical conditions. e.g., liver insufficiency, kidney insufficiency, cardiovascular problems \[unstable arrhythmias, chronic heart failure, myocardial infarction (MI), cardiac pacemaker\], systemic infections, cancer, active upper respiratory infections, endocrinopathies, and any major neurological disorder \[e.g., seizure disorder, stroke, dementia, degenerative neurologic diseases, traumatic brain injury\]. 7. Any medical contraindication to surgery or condition that makes the patient, in the opinion of the surgeon, a poor candidate. 8. Female who is pregnant or breastfeeding or has plans to become pregnant in the next 24 months. 9. Any contraindication for MRI. 10. Patients with a clinically significant personality disorder, including risk for homicidal or aggressive behavior, which in the opinion of the investigator has a major impact on the patient's current psychiatric status and/or would preclude safe study participation. 11. Patients at serious and imminent risk of suicide and not suitable for an outpatient study, in the judgment of the investigators. 12. Participation in any investigational clinical trial within the preceding 30 days. 13. Current implanted stimulation devices including cardiac pacemakers, defibrillators, and neurostimulators \[including deep brain and spinal cord stimulators\]. 14. Patients with no regular contact with at least one adult. Patients who are undomiciled are excluded. 15. Body mass index (BMI) less than 16 and greater than 40 kg/m2 16. Need for diathermy. 17. Unable to sign the informed consent for any reason. 18. Patients who are not under the care of a psychiatrist at Screening and throughout the duration of the study.
Conditions Gastroesophageal Cancer (GC), Postoperat...
Phase Not Applicable
Enrollment 130
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this observational study is to investigate the incidence of Post Operative Delirium (POD) after gastroesophageal cancer surgery. Secondary objectives are to investigate the relationship between POD, preoperative depression, frailty, quality of life, malnutrition and sarcopenia. Participants identified with POD will be asked (at the routine follow-up meeting after surgery) to participate in an qualitative interview, in order to understand the participant's experience of postoperative delirium. The main objective aims to answer: What is the incidence of POD after gastroesophageal cancer surgery.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Incidence of postoperative delirium (From enrollment to the follow up meeting after surgery, approximate 6 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-13
Completion: 2028-11-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 130 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Karolinska Institutet
Collaborators: Region Stockholm
Principal Investigators:
  • Maria Lampi, PhD (PRINCIPAL_INVESTIGATOR) - Karolinska Institutet
Contact Information
Study Contact:
Marcus Nömm, PhD-student
0733765652
marcus.nomm@ki.se
Maria Lampi, PhD
0852483721
maria.lampi@ki.se
Marcus Nömm PhD-student
0733765652
marcus.nomm@ki.se
Karolinska University Hospital, Huddinge
Interventions
N/A
Study Locations (1 sites)
Karolinska University Hospital, Huddinge, Huddinge, 14157 Sweden
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with esophageal or gastric cancer, treated with (or without) chemotherapy and surgery. * Age ≥18 at the time for inclusion. * Participate on a voluntary basis and can (for any reason) end its participation during the study. * Capable of giving informed consent. Exclusion Criteria: * Patients with preoperative cognitive dysfunction such as dementia. * Patients who are inoperable due to metastases. * Patients unable to communicate due to severely impaired hearing and/or - seeing. * Patients with ongoing drug and/or alcohol abuse. * Patients who cannot give informed consent.
Conditions Breast Cancer Related Lymphedema
Phase NA
Enrollment 31
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the most common type of cancer among women globally and has the highest mortality rate. Surgical interventions are typically required in the treatment of breast cancer, but these procedures can lead to complications such as infection, seroma, hematoma, cellulitis, and particularly lymphedema due to disruptions in the physiology of axillary lymphatic vessels. Breast Cancer-Related Lymphedema (BCRL) commonly develops within the first two years following surgical intervention and its incidence varies depending on the surgical method used. The incidence of lymphedema after Sentinel Lymph Node Biopsy (SLNB) is around 5%, whereas it increases to 30-50% after Axillary Lymph Node Dissection (ALND). BCRL significantly impacts the quality of life (QoL) through physical symptoms such as swelling, pain, tightness, and limited range of motion, as well as psychosocial issues including depression, social isolation, and sleep disturbances. Sleep disorders, in particular, are associated with depression and contribute to a further decline in QoL. In the treatment of BCRL, both conservative (non-surgical) and surgical methods are traditionally employed. Complex Decongestive Physiotherapy (CDP) is considered the gold standard for the conservative management of lymphedema. CDP comprises a two-phase treatment process. The first phase, known as the "Decongestion Phase," generally lasts 2-4 weeks and includes manual lymphatic drainage (MLD), skin care, compression therapy with multi-layered short-stretch bandages, and muscle-pumping exercises. The second phase, the "Maintenance Phase," is more prolonged and aims to sustain the results achieved in Phase 1. It includes compression with low-stretch elastic garments, skin care, exercises, and patient-administered MLD as needed. The primary objectives of CDP are to improve lymphatic circulation, reduce swelling, pain, and tightness, increase the range of motion, and ultimately improve the QoL. Studies have shown that CDP significantly enhances sleep quality and QoL in women with BCRL. However, most existing studies examine all stages of BCRL without comparing the effects of CDP across different stages. The impact of CDP on sleep and QoL may vary depending on the stage of BCRL, highlighting the need for specific research on its effects in particular populations. Furthermore, many studies lack follow-up data, leaving the Maintenance Phase of CDP largely unexplored. This study aims to investigate the effects of CDP, including both the Decongestion and Maintenance phases, on sleep quality and QoL specifically in women with Stage II BCRL.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Physiotherapy and rehabilitation — Complex Decongestive Physiotherapy (CDP) Complex Decongestive Physiotherapy (CDP) consists of Manual Lymphatic Drainage (MLD), skin care, compression bandaging, and exercise, which are routinely used in clinical practice (9). CDP sessions will last approximately one hour each and will be administered for 4 weeks, with 5 sessions per week, totaling 20 sessions. Manual Lymphatic Drainage (MLD) is a massage technique involving rhythmic, gentle pressure movements aimed at reducing the accumulation of lymphatic fluid in conditions such as lymphedema. This therapy facilitates the drainage of lymphatic fluid into the body's primary lymphatic pathways, thereby reducing edema, pain, and tightness, while enhancing range of motion and overall quality of life. MLD typically focuses on areas with a high concentration of lymph nodes, promoting the smooth circulation of lymph fluid. Treatment sessions usually last between 30 minutes to one hour.

Primary Outcomes

  • Sleep Quality (Baseline, 4th week and 1 month follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-01
Completion: 2027-03-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 31 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Abant Izzet Baysal University
Contact Information
Study Contact:
Elif DUYGU, PhD
+905052539010
elifduygu@ibu.edu.tr
Zeynep DURU, MSc
+905344095717
zeyneppdduru@gmail.com
Ramazan KURUL, PhD
+905436414731
ramazankurul@ibu.edu.tr
Bolu Abant Izzet Baysal University
Interventions
  • Other: Physiotherapy and rehabilitation — Complex Decongestive Physiotherapy (CDP) Complex Decongestive Physiotherapy (CDP) consists of Manual Lymphatic Drainage (MLD), skin care, compression bandaging, and exercise, which are routinely used in clinical practice (9). CDP sessions will last approximately one hour each and will be administered for 4 weeks, with 5 sessions per week, totaling 20 sessions. Manual Lymphatic Drainage (MLD) is a massage technique involving rhythmic, gentle pressure movements aimed at reducing the accumulation of lymphatic fluid in conditions such as lymphedema. This therapy facilitates the drainage of lymphatic fluid into the body's primary lymphatic pathways, thereby reducing edema, pain, and tightness, while enhancing range of motion and overall quality of life. MLD typically focuses on areas with a high concentration of lymph nodes, promoting the smooth circulation of lymph fluid. Treatment sessions usually last between 30 minutes to one hour.
Study Locations (2 sites)
Bolu Abant Izzet Baysal University, Bolu, 14030 Turkey (Türkiye)
Bolu Abant Izzet Baysal University, Bolu, 14030 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Participants must be aged between 18 or 85 years, * with a diagnosis of unilateral lymphedema in the upper extremity following breast cancer surgery * stage 2 lymphedema confirmed by a doctor * voluntary consent to participate in the study. Exclusion Criteria: * refusal to participate in the study * development of lymphedema due to primary causes, presence of bilateral upper extremity lymphedema * active soft tissue infection in the lymphedematous arm * mental or cognitive disorders * inability to communicate or cooperate * acute deep vein thrombosis, arterial insufficiency in the upper extremity, systemic diseases that could cause edema other than lymphedema (e.g., renal failure, liver failure, heart failure) * use of sleep medications or antidepressants
Conditions Triple Negative Breast Cancer
Phase PHASE2
Enrollment 45
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Triple-negative breast cancer (TNBC) is among the most aggressive and lethal types of breast cancer, and currently available therapies have an unsatisfactory impact on patients' survival. The primary aim of this clinical trial is to evaluate efficacy in terms of Overall Response Rate (ORR) of atezolizumab plus cyclophosphamide and vinorelbine in first line patients with unresectable locally advanced or metastatic TNBC patients, previously treated with anti-programmed cell death ligand-1 (PD-L1) or anti-programmed cell death-1 (PD-1) - containing regimens, in the neoadjuvant/adjuvant setting.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Atezolizumab in combination with Cyclophosphamide and Vinorelbine — Patients will receive Atezolizumab in combination with Cyclophosphamide and Vinorelbine in 28-day cycles

Primary Outcomes

  • Overall Response Rate (ORR) (30 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-03-06
Completion: 2027-02-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Institute of Oncology
Principal Investigators:
  • Elisabetta Munzone, MD (PRINCIPAL_INVESTIGATOR) - European Istitute of Oncology
  • Francesco Bertolini (PRINCIPAL_INVESTIGATOR) - European Istitute of Oncology
Contact Information
Study Contact:
Elisabetta Munzone, MD
+39 0257489405
elisabetta.munzone@ieo.it
Mara Negri
+39 0257489536
mara.negri@ieo.it
Maria Elena Cazzaniga, MD
00390392339037
marina.cazzaniga@irccs-sangerardo.it
Fondazione IRCCS San Gerardo Dei Tintori
Interventions
  • Drug: Atezolizumab in combination with Cyclophosphamide and Vinorelbine — Patients will receive Atezolizumab in combination with Cyclophosphamide and Vinorelbine in 28-day cycles
Study Locations (5 sites)
Fondazione IRCCS San Gerardo Dei Tintori, Monza, Monza 20900 Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Roma 00168 Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Roma 00168 Italy
Azienda Sanitaria Locale Br, Brindisi, Italy
European Institute of Oncology, Milan, 20141 Italy
Eligibility Criteria
Inclusion Criteria: * Signed Informed Consent Form * Patients with locally advanced or metastatic, histologically documented TNBC (absence of human epidermal growth factor 2 \[HER2\], estrogen receptor \[ER\], and progesterone receptor \[PR\] expression) PD-L1+ (Immune Cell \>1% using Ventana SP142 assay), not amenable to surgical therapy * Locally advanced or metastatic TNBC, who have received an anti-PD-1/PD-L1 containing regimen in the neoadjuvant/adjuvant setting * No prior chemotherapy or targeted systemic therapy (including endocrine therapy) or immunotherapy for inoperable locally advanced or metastatic TNBC * Tissue accessible for biopsies * Expected survival of \> 3 months * Female or male subject ≥18 years * Have measurable/evaluable metastatic disease (RECIST 1.1 criteria) * Performance status 0-1 on Eastern Cooperative Oncology Group Performance Status (ECOG PS) * Demonstrate adequate organ (kidney, liver) function Exclusion Criteria: * Patients with de novo metastatic TNBC OR those who have received 1 or more chemotherapy or targeted systemic therapy (including endocrine therapy) or immunotherapy regimens for advanced disease * Immunodeficiency or systemic steroid therapy/immunosuppressive therapy within 7 days prior to study entry * Known history of active Bacillus Tuberculosis (TBC) * Hypersensitivity to anti- PD-L1 antibodies or its excipients * Active autoimmune disease * Known history of non-infectious pneumonitis * Active infection requiring systemic therapy * Known history of Human Immunodeficiency Virus (HIV) * Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\]) * Live vaccine within 30 days * Bone or brain metastases
Conditions Type 2 Diabetes Mellitus, Obesity
Phase NA
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Globally, chronic noncommunicable diseases rank as the leading cause of morbidity and mortality. Diabetes is reaching high epidemic proportions across the globe. The prevalence of diabetes is increasing in Saudi Arabia, with diabetes affecting 14.1% of the population across all age groups and 28% of those over the age of 30. Date seed intake is one of the best-studied patterns. Previous studies findinds showed that the phenolic compounds in date seeds have blood sugar-lowering properties. There is a lack of data on how date seed diets may affect glycaemia control and cardiovascular risk among Saudi Arabian patients with T2DM. Therefore, randomised controlled trials (RCTs) will be conducted to assess the effects of date seeds on glycaemic control and cardiovascular risk among diabetes patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Other: Date Seed Extract — Intervention group participants will undergo a three-month intervention program. The Health Belief Model (HBM) will be the underlying theory to facilitate behaviour change. The intervention group will receive a capsule of date-seed-powder. Each person should consume 5 grams (two capsules of date-seed powder)twice daily after meals for three months. Assessments are carried out at the beginning of the study, one month and two months after the intervention on the effect of date-seed on glycaemic control,risk of cardiovascular, physical activity, daytime sleepiness and anthropometric measurements. Participants will be contacted twice a week to ensure that they are adhering to the rules.

Primary Outcomes

  • Change in Blood Glucose Levels ([Time Frame: Timepoint 1 = Baseline. Repeated measurement: Timepoint 2 = week 12 (12-week post intervention)])
  • Change in cholesterol Levels ([Time Frame: Timepoint 1 = Baseline. Repeated measurement: Timepoint 2 = week 12 (12-week post intervention)])
  • Change in Blood Pressure ([Time Frame: Timepoint 1 = Baseline. Repeated measurement: Timepoint 2 = week 12 (12-week post intervention)])
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-01
Completion: 2025-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universiti Putra Malaysia
Principal Investigators:
  • Zuriati Ibrahim, PhD (PRINCIPAL_INVESTIGATOR) - UniversitI Putra Malaysia (UPM), 43400 Serdang, Selangor, Malaysia
Contact Information
Study Contact:
Maha Aldaham, Master
+60176652101
maaaldaham8@gmail.com
Zuriati Ibrahim, PhD
+603-97692464
zuriatiib@upm.edu.my
Dr Zuriati Ibrahim, PhD
+603-97692464
zuriatiib@upm.edu.my
Dr Zuriati Ibrahim
Interventions
  • Other: Date Seed Extract — Intervention group participants will undergo a three-month intervention program. The Health Belief Model (HBM) will be the underlying theory to facilitate behaviour change. The intervention group will receive a capsule of date-seed-powder. Each person should consume 5 grams (two capsules of date-seed powder)twice daily after meals for three months. Assessments are carried out at the beginning of the study, one month and two months after the intervention on the effect of date-seed on glycaemic control,risk of cardiovascular, physical activity, daytime sleepiness and anthropometric measurements. Participants will be contacted twice a week to ensure that they are adhering to the rules.
Study Locations (1 sites)
Dr Zuriati Ibrahim, Serdang, Selangor 43400 Malaysia
Eligibility Criteria
Inclusion Criteria: * Aged 18 years old and above. * Diagnosis of Type 2 diabetes. * Receiving and monitoring diabetes care from diabetes center. * With stable HbA1c less than 10% (no episode of hypoglycaemia, no hospitalisation, no change in type or dosage of medication use for at least 6 months). Exclusion Criteria: * Pregnant or lactating women. * Diagnosis of cardiac failure or/and severe renal disease, with physical or mental disability, neurological or cognitive impairment. * Participant with severely impaired vision, hearing, or speech. * Participants who have known allergy to dates products.